Regorafenib (R) in advanced solitary fibrous tumor (SFT): Results from an exploratory phase II clinical study.
Volume: 39, Issue: 15_suppl, Pages: 11558 - 11558
Published: May 20, 2021
Abstract
11558 Background: R showed antitumor activity in a PDX model of dedifferentiated SFT (D-SFT), inducing a superior tumour growth inhibition than with other antiangiogenic agents (A), such as pazopanib (P) and axitinib (A). The efficacy of P and A in patients (pts) with advanced typical- (T-)/ malignant- (M-)SFT has been already confirmed in phase 2 clinical trials, but not in D-SFT. An exploratory phase 2 study was designed to investigate the...
Paper Details
Title
Regorafenib (R) in advanced solitary fibrous tumor (SFT): Results from an exploratory phase II clinical study.
Published Date
May 20, 2021
Journal
Volume
39
Issue
15_suppl
Pages
11558 - 11558
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History